GSK Completes Divestment of Anesthesia Portfolio
GlaxoSmithKline (GSK) has completed the previously announced divestiture of its anesthesia portfolio to Aspen Pharma, a pharmaceutical company headquartered in KwaZulu-Natal, South Africa, for £180 million ($221 million) plus milestones of up to £100 million ($123 million). The divestiture, which GSK announced in September 2016, excludes the US and Canada, which had been previously divested.
GSK’s anesthesia portfolio consists of Ultiva (remifentanil), Nimbex (cisatracurium besylate), Tracrium (atracurium besylate), Mivacron (mivacurium chloride), and Anectine (succinylcholine chloride). The portfolio had 2016 full year sales of approximately £70 million ($86 million).
In addition to the anesthesia portfolio divestment, GSK and Aspen entered into parallel agreements in September 2016 to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets. Following this termination, both parties will continue to commercialize their own respective portfolios in the region. The collaboration between GSK and Aspen in South Africa remains in place.